Arcturus Therapeutics (NASDAQ:ARCT) Trading 3.4% Higher

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price shot up 3.4% during mid-day trading on Tuesday . The stock traded as high as $30.42 and last traded at $30.32. 97,867 shares traded hands during trading, a decline of 78% from the average session volume of 448,974 shares. The stock had previously closed at $29.31.

Analyst Ratings Changes

A number of analysts have recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Citigroup upped their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.33.

Arcturus Therapeutics Trading Up 3.9 %

The business has a 50 day moving average of $35.77 and a two-hundred day moving average of $29.73. The firm has a market cap of $819.44 million, a P/E ratio of -27.96 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. The company had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -1.42 EPS for the current year.

Insiders Place Their Bets

In related news, COO Pad Chivukula sold 8,565 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total transaction of $299,860.65. Following the completion of the sale, the chief operating officer now directly owns 490,883 shares of the company’s stock, valued at approximately $17,185,813.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. grew its holdings in shares of Arcturus Therapeutics by 1.8% during the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock worth $101,421,000 after purchasing an additional 66,971 shares in the last quarter. State Street Corp increased its stake in shares of Arcturus Therapeutics by 56.5% in the first quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company’s stock valued at $86,756,000 after buying an additional 1,161,883 shares during the period. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock valued at $64,564,000 after buying an additional 146,141 shares during the period. BlackRock Inc. grew its holdings in Arcturus Therapeutics by 10.9% during the 2nd quarter. BlackRock Inc. now owns 1,992,235 shares of the biotechnology company’s stock worth $57,137,000 after acquiring an additional 195,918 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Arcturus Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,458,380 shares of the biotechnology company’s stock worth $45,983,000 after purchasing an additional 51,537 shares during the period. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.